Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.
1. Eight women with acute pyelonephritis were treated with i.v. enoxacin for 5 days. All were clinically cured and five had a bacteriological cure. Five women reported side effects. 2. During treatment there was no significant accumulation of enoxacin and the total clearance of the drug did not alter with repeated dosing. Drug elimination half-life (mean 4.3 h, s.d. 2.1) was similar to that reported in healthy volunteers. 3. Enoxacin should be compared with the aminoglycosides and beta-lactam antibiotics for the treatment of severe or complicated urinary tract infections.
Bailey
R R
RR
Department of Nephrology, Christchurch Hospital, New Zealand.
Walker
R J
RJ
Lynn
K L
KL
Donaldson
I M
IM
Peddie
B A
BA
Dobbs
B R
BR
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015365:Enoxacin; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009287:Naphthyridines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy*
D000892:Anti-Infective Agents, Urinary; D009287:Naphthyridines; D015365:Enoxacin